Clinical trials for the safety and efficacy of the combination of XELOX,the colorectal cancer radical resection adjuvant chemotherapy and of chronic hepatitis therapeutic agent 3 oxygelmillpropionic acid polymer.(Phase 1 test)
- Conditions
- Colorectal cancer
- Registration Number
- JPRN-UMIN000022440
- Lead Sponsor
- Osaka University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 5
Not provided
1) Patients who could not resect curatively. 2) Patients with active double cancer. 3) Patients with severe drug hypersensitivity, or with a history of drug allergy. 4) Patients with serious complications (heart failure, renal failure, liver failure, bleeding ulcer, watery diarrhea, intestinal paralysis, intestinal obstruction, severe diabetes). 5)Patients of cirrhosis with jaundice or of suspected cirrhosis of the liver. 6)Patients with the history of chronic hepatitis B and with the experience of Seroshion. 7)Patients with active infection. 8)Women with the possibility of pregnancy,during pregnancy,with the hope of pregnancy,or with breast-feeding. 9)Patients with mental severe disorder. 10)Other cases who doctor determines that patients are unsuitable for safely carrying out the present study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety
- Secondary Outcome Measures
Name Time Method